Blinatumomab
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Conditions
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Trial Timeline
— → —
NCT ID
NCT02187354About Blinatumomab
Blinatumomab is a pre-clinical stage product being developed by Amgen for Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02187354. Target conditions include Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02187354 | Pre-clinical | Completed |
| NCT07192237 | Phase 2 | Recruiting |
| NCT07134088 | Phase 1/2 | Recruiting |
| NCT06649006 | Phase 1 | Completed |
| NCT06054113 | Phase 2 | Active |
| NCT04448834 | Phase 2 | Withdrawn |
| NCT04506086 | Approved | Terminated |
| NCT04746209 | Phase 2 | Recruiting |
| NCT04521231 | Phase 1/2 | Recruiting |
| NCT04556084 | Phase 2 | Terminated |
| NCT04785547 | Phase 2 | Terminated |
| NCT04044560 | Phase 2 | Terminated |
| NCT03751709 | Phase 1 | Completed |
| NCT03298412 | Phase 2 | Terminated |
| NCT02961881 | Phase 1 | Completed |
| NCT02910063 | Phase 2/3 | Completed |
| NCT02807883 | Phase 2 | Completed |
| NCT02811679 | Phase 2 | Terminated |
| NCT02412306 | Phase 1/2 | Completed |
| NCT02000427 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia